AEON Biopharma (NASDAQ:AEON) Stock: Insider Alexander Blair Wilson Acquires 135,706 Shares

AEON Biopharma, Inc. (NASDAQ:AEON – Get Free Report) insider Alexander Blair Wilson purchased 135,706 shares of the stock in a transaction dated Friday, November 20th. The shares were acquired at an average cost of $0.13 per share, for a total transaction of $17,641.78. Following the completion of the acquisition, the insider owned 2,318,711 shares of the company’s stock, valued at approximately $301,432.43. This represents a 6.22% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

AEON Biopharma Price Performance

AEON Biopharma stock opened at $0.12 on Friday. AEON Biopharma, Inc. has a one year low of $0.11 and a one year high of $1.45. The stock has a market capitalization of $8.80 million, a PE ratio of 0.68 and a beta of 0.68. The business’s fifty day moving average is $0.23 and its 200 day moving average is $0.60.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Laidlaw initiated coverage on shares of AEON Biopharma in a research note on Wednesday, September 9th. They set a “buy” rating and a $1.80 target price on the stock. Lake Street Capital reiterated a “buy” rating and issued a $2.00 price target (up from $1.00) on shares of AEON Biopharma in a research note on Thursday, October 1st. Finally, HC Wainwright reissued a “buy” rating and set a $1.20 price objective (down from $5.00) on shares of AEON Biopharma in a report on Friday, August 14th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1.67.

Check Out Our Latest Research Report on AEON

Hedge Funds Weigh In On AEON Biopharma

An institutional investor recently bought a new position in AEON Biopharma stock. Nantahala Capital Management LLC acquired a new stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,400,000 shares of the company’s stock, valued at approximately $1,298,000. Nantahala Capital Management LLC owned about 8.82% of AEON Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 22.78% of the stock is currently owned by institutional investors.

AEON Biopharma Company Profile

(Get Free Report)

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions using botulinum toxin. Its lead candidate, ABP-450, is an investigational botulinum toxin type A product being studied for therapeutic uses. The company’s development programs include chronic migraine and cervical dystonia. ABP-450 is not an approved treatment for these conditions, and its safety and effectiveness have not been established for these uses. AEON has described its rights to develop and commercialize ABP-450 for therapeutic indications in the United States and Canada.

Read More

Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.